Microglia rescue neurons from aggregate-induced neuronal dysfunction and death through tunneling nanotubes.

Lrrk2 G2019S Trem2 alpha-synuclein intercellular transfer microglia mitochondria neurons oxidative stress tau tunneling nanotubes

Journal

Neuron
ISSN: 1097-4199
Titre abrégé: Neuron
Pays: United States
ID NLM: 8809320

Informations de publication

Date de publication:
23 Jul 2024
Historique:
received: 26 10 2023
revised: 12 02 2024
accepted: 28 06 2024
medline: 27 7 2024
pubmed: 27 7 2024
entrez: 26 7 2024
Statut: aheadofprint

Résumé

Microglia are crucial for maintaining brain health and neuron function. Here, we report that microglia establish connections with neurons using tunneling nanotubes (TNTs) in both physiological and pathological conditions. These TNTs facilitate the rapid exchange of organelles, vesicles, and proteins. In neurodegenerative diseases like Parkinson's and Alzheimer's disease, toxic aggregates of alpha-synuclein (α-syn) and tau accumulate within neurons. Our research demonstrates that microglia use TNTs to extract neurons from these aggregates, restoring neuronal health. Additionally, microglia share their healthy mitochondria with burdened neurons, reducing oxidative stress and normalizing gene expression. Disrupting mitochondrial function with antimycin A before TNT formation eliminates this neuroprotection. Moreover, co-culturing neurons with microglia and promoting TNT formation rescues suppressed neuronal activity caused by α-syn or tau aggregates. Notably, TNT-mediated aggregate transfer is compromised in microglia carrying Lrrk22(Gly2019Ser) or Trem2(T66M) and (R47H) mutations, suggesting a role in the pathology of these gene variants in neurodegenerative diseases.

Identifiants

pubmed: 39059388
pii: S0896-6273(24)00491-4
doi: 10.1016/j.neuron.2024.06.029
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests E.L. is a co-founder and advisor at IFM Therapeutics, and M.T.H. serves as an advisory board member at IFM Therapeutics, T3D, and Alector.

Auteurs

Hannah Scheiblich (H)

Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases, Bonn, Germany; Max-Planck-Institute for Biology of Ageing, Cologne, Germany.

Frederik Eikens (F)

Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases, Bonn, Germany; Max-Planck-Institute for Biology of Ageing, Cologne, Germany.

Lena Wischhof (L)

German Center for Neurodegenerative Diseases, Bonn, Germany; Max-Planck-Institute for Biology of Ageing, Cologne, Germany.

Sabine Opitz (S)

Institute of Neuropathology, University of Bonn, Bonn, Germany.

Kay Jüngling (K)

Institute of Physiology I, Westfälische Wilhelms-University Münster, Münster, Germany.

Csaba Cserép (C)

Institute of Experimental Medicine, Budapest, Hungary.

Susanne V Schmidt (SV)

Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.

Jessica Lambertz (J)

Institute of Anatomy, University Hospital Bonn, Bonn, Germany.

Tracy Bellande (T)

Institut François Jacob, CEA and Laboratory of Neurodegenerative Diseases, Fontenay-aux-Roses, France.

Balázs Pósfai (B)

Institute of Experimental Medicine, Budapest, Hungary.

Charlotte Geck (C)

Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.

Jasper Spitzer (J)

Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.

Alexandru Odainic (A)

Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection & Immunity, University of Melbourne, Melbourne, VIC, Australia.

Sergio Castro-Gomez (S)

Institute of Physiology II, University Hospital Bonn, Bonn, Germany.

Stephanie Schwartz (S)

Institute of Physiology II, University Hospital Bonn, Bonn, Germany.

Ibrahim Boussaad (I)

Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg.

Rejko Krüger (R)

Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg.

Enrico Glaab (E)

Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg.

Donato A Di Monte (DA)

German Center for Neurodegenerative Diseases, Bonn, Germany.

Daniele Bano (D)

German Center for Neurodegenerative Diseases, Bonn, Germany.

Ádám Dénes (Á)

Institute of Experimental Medicine, Budapest, Hungary.

Eike Latz (E)

German Center for Neurodegenerative Diseases, Bonn, Germany; Institute of innate immunity, University Hospital Bonn, Bonn, Germany.

Ronald Melki (R)

Institut François Jacob, CEA and Laboratory of Neurodegenerative Diseases, Fontenay-aux-Roses, France.

Hans-Christian Pape (HC)

Institute of Physiology I, Westfälische Wilhelms-University Münster, Münster, Germany.

Michael T Heneka (MT)

German Center for Neurodegenerative Diseases, Bonn, Germany; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg; Institute of innate immunity, University Hospital Bonn, Bonn, Germany; Department of Infectious Diseases and Immunology, University of Massachusetts, Medical School, Worcester, MA, USA. Electronic address: michael.heneka@uni.lu.

Classifications MeSH